Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Multicentre, open label, phase III study. Subjects with moderate to severe psoriasis were
given efalizumab subcutaneously once per week for the 12-week treatment period. Assessments
involved physical examination, disease activity assessments, clinical laboratory tests
(haematology, blood chemistry and standard urinalysis), evaluation of the Psoriasis Area and
Severity Index (PASI), the Physician's Global Assessment (PGA), the Patient's Global
Psoriasis Assessment (PGPA), the SF-36 Health Survey and psoriatic body surface area (BSA).
The 12-week treatment period was followed by a 12-week follow-up (FU) period, during which
other antipsoriatic medications were allowed. The same assessments were also performed in the
12-week FU period.